Type 2 Diabetes Mellitus (T2DM) is a worldwide chronic disease, related to high morbidity and mortality, and to significant quality of life deterioration. It is frequently associated not only with acute decompensations but also with chronic complications such as cardiovascular problems, renal disease, neuropathy, foot ulcer and loss of vision. The existence of comorbidities and complications not only increases mortality, but also the risk of hospitalizations, the average inpatient stay length, and the amount of illness related productivity losses. This, in turn, has an impact on direct and indirect costs associated to T2DM. Cost studies are relevant for policymakers, since they assess the impact of a disease in monetary terms and help budget allocation decision making. They are specially useful in the context of highly prevalent chronic diseases, such as DM. Many empirical studies have measured the magnitude of the cost of DM in different countries. However, results vary significantly, primarily because of methodological disparities.
This study was conducted by Max Weber Institute, an independent consulting company, and received funds from Sanofi.
We searched relevant databases (Pubmed and Scielo) for studies estimating DM (both Type 1 and Type 2) costs, published in English and Spanish in the USA and Europe (in the period 2000-2014). Search terms included "diabetes", "costs", "burden", and "economic impact". Cost drivers and differences in methodologies across studies were identified. No exclusion was made based on study design, but we excluded studies that conveyed results only at the aggregate level with no description of the cost factors included in the analysis.
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The objective of this literature review is to identify the main drivers that influence the costs of T2DM, by comparing the different costing methodologies used in published cost studies, and the subsequent cost results. This literature review was carried out as a starting point in the development of future methodological guidelines for estimating the costs of T2DM in Spain.
Hospitalizations are a key cost driver. Their relative weight on direct healthcare costs range between 13% and 57% (mean weight of 41%) depending on the other categories included and on the scope of this component (hospital stays only due to diabetes decompensations or also due to T2DM complications).
There are other cost components that may also have a significant impact over direct sanitary costs. Supplies may reach up to 9%, nursing care 11%, emergency care 16%, the use of diagnostic procedures 27% and care at home up to 40% (although its usual weight rounds 3-4%).
Complications of T2DM are responsible for between 40% and 85% of hospitalization costs, therefore substantially increasing total costs, especially if both types of complications (micro and macrovascular) are taken into account .
Hypoglycemic events are also an important T2DM cost driver, since they cause direct costs related to the management and follow-up of the acute event. Likewise, they are often related to reduced productivity, absenteeism and occasionally early retirement, as well as significant intangible costs such as pain and suffering.
Optimal glycemic control is proved to reduce costs. However, this cost driver is rarely considered in the studies. A recent bottom-up study developed in Spain 3 finds that the average annual direct healthcare cost per diabetic patient may differ by up to 16% depending on his/her glycemic control level (set at HbA1c ≤ 7%).
Non direct healthcare costs were measured in 6 out of the 24 identified studies. They refer to those costs incurred by the patient or his/her family due to transportation to the healthcare center and to the costs of caregiving (formal and informal). While the magnitude of transportation costs is usually limited, caregiving costs may be significant (up to 17% of total costs). However, there is a high variability in results, derived from methodological differences.
In terms of indirect costs, 10 of the studies included some measure of productivity loss caused by T2DM's associated mortality or morbidity. If included, indirect costs may represent between 25% and 50% of total costs. The most common indirect cost included is the disability caused by T2DM, especially the temporary disability, responsible for between 5% and 57% of total productivity losses. Presenteeism (attending work while sick, therefore with a lower productivity) due to T2DM was included in 4 studies, and stood for up to 34% of total indirect costs. The inclusion of these costs depends on the perspective of the study. They are usually omitted in studies carried out from a healthcare services perspective since they are less crucial for healthcare decision makers.
Direct healthcare costs were included in all the identified cost studies. They range between 43% and 100% of total costs, depending partially on whether indirect and caregiving costs are also considered.
The most frequently measured cost components are hospitalizations, medication and medical visits (see Graph 1); while home healthcare provision, diagnostic tests, nurse visits, emergency visits and control material or supplies are less common. Some cost studies also include visits to other healthcare professionals (physiotherapist, podiatrist, dietitian), materials (glasses) or nursing homes stays.
Physician office visits were included in all but two studies. This item generally included visits both to the general practitioner and to medical specialists, and represented between 8% and 36% of the average annual cost per diabetic patient.
Pharmacologic costs range between 16% and 51% of direct healthcare costs, depending on whether they are measured in a relatively restricted way (including only insulin and oral antidiabetic drugs) or whether include all costs involved in the prevention and treatment of the disease and its complications. 
